Sinonasal malignancy: ESMO-EURACAN Clinical Practice Guideline
for diagnosis, treatment and follow-up

J 2025

Sinonasal malignancy: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up

RESTEGHINI, C.; B. BAUJAT; P. BOSSI; A. FRANCHI; L. DE GABORY et al.

Základní údaje

Originální název

Sinonasal malignancy: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up

Autoři

Vydání

ESMO OPEN, AMSTERDAM, ELSEVIER, 2025, 2059-7029

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Nizozemské království

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 8.300 v roce 2024

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/25:00140943

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

endoscopic surgery; (neoadjuvant) chemotherapy; radiotherapy; proton therapy; sinonasal carcinomas

Štítky

14110811, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 3. 4. 2025 10:44, Mgr. Tereza Miškechová

Anotace

V originále

The term sinonasal malignancies (SMs) groups together many tumours of variable histology and biological behaviour. This Clinical Practice Guideline (CPG) covers the histotypes included in the fifth edition of the World Health Organization classification of tumours of the nasal cavity, paranasal sinuses and skull base (see Supplementary Table S1, available at https://doi.org/10.1016/j.esmoop.2024.104121) under ‘carcinomas’, ‘adenocarcinomas’ and ‘olfactory neuroblastomas’. Additionally, this CPG covers neuroendocrine carcinomas rising in this area such as small-cell neuroendocrine carcinoma (SCNEC) and large-cell sinonasal neuroendocrine carcinoma (SNEC). Salivary-type malignancies, mesenchymal tumours and mucosal melanoma of the sinonasal tract have been excluded, since dedicated guidelines already exist.

Citovat

RESTEGHINI, C.; B. BAUJAT; P. BOSSI; A. FRANCHI; L. DE GABORY; Jana HALÁMKOVÁ; F. HAUBNER; J. A. U. HARDILLO; M. A. HERMSEN; N A. IACOVELLI; R. MAROLDI; S. MATTHEIS; A. MOYA-PLANA; P. NICOLAI; E. ORLANDI; J. THARIAT; A. TRAMA; M. W. M. VAN DEN BREKEL; C. M. L. VAN HERPEN; B. VERILLAUD; E. KINLOCH; L. LICITRA a C. EVEN. Sinonasal malignancy: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up. ESMO OPEN. AMSTERDAM: ELSEVIER, 2025, roč. 10, č. 2, s. 1-15. ISSN 2059-7029. Dostupné z: https://doi.org/10.1016/j.esmoop.2024.104121.

@article{2488679,
   author = {Resteghini, C. and Baujat, B. and Bossi, P. and Franchi, A. and de Gabory, L. and Halámková, Jana and Haubner, F. and Hardillo, J. A. U. and Hermsen, M. A. and Iacovelli, N A. and Maroldi, R. and Mattheis, S. and MoyaandPlana, A. and Nicolai, P. and Orlandi, E. and Thariat, J. and Trama, A. and van den Brekel, M. W. M. and van Herpen, C. M. L. and Verillaud, B. and Kinloch, E. and Licitra, L. and Even, C.},
   article_location = {AMSTERDAM},
   article_number = {2},
   doi = {https://doi.org/10.1016/j.esmoop.2024.104121},
   keywords = {endoscopic surgery; (neoadjuvant) chemotherapy; radiotherapy; proton therapy; sinonasal carcinomas},
   language = {eng},
   issn = {2059-7029},
   journal = {ESMO OPEN},
   title = {Sinonasal malignancy: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up},
   url = {https://www.sciencedirect.com/science/article/pii/S2059702924018921?via%3Dihub},
   volume = {10},
   year = {2025}
}

TY  - JOUR
ID  - 2488679
AU  - Resteghini, C. - Baujat, B. - Bossi, P. - Franchi, A. - de Gabory, L. - Halámková, Jana - Haubner, F. - Hardillo, J. A. U. - Hermsen, M. A. - Iacovelli, N A. - Maroldi, R. - Mattheis, S. - Moya-Plana, A. - Nicolai, P. - Orlandi, E. - Thariat, J. - Trama, A. - van den Brekel, M. W. M. - van Herpen, C. M. L. - Verillaud, B. - Kinloch, E. - Licitra, L. - Even, C.
PY  - 2025
TI  - Sinonasal malignancy: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up
JF  - ESMO OPEN
VL  - 10
IS  - 2
SP  - 1-15
EP  - 1-15
PB  - ELSEVIER
SN  - 20597029
KW  - endoscopic surgery
KW  - (neoadjuvant) chemotherapy
KW  - radiotherapy
KW  - proton therapy
KW  - sinonasal carcinomas
UR  - https://www.sciencedirect.com/science/article/pii/S2059702924018921?via%3Dihub
N2  - The term sinonasal malignancies (SMs) groups together many tumours of variable histology and biological behaviour. This Clinical Practice Guideline (CPG) covers the histotypes included in the fifth edition of the World Health Organization classification of tumours of the nasal cavity, paranasal sinuses and skull base (see Supplementary Table S1, available at https://doi.org/10.1016/j.esmoop.2024.104121) under ‘carcinomas’, ‘adenocarcinomas’ and ‘olfactory neuroblastomas’. Additionally, this CPG covers neuroendocrine carcinomas rising in this area such as small-cell neuroendocrine carcinoma (SCNEC) and large-cell sinonasal neuroendocrine carcinoma (SNEC). Salivary-type malignancies, mesenchymal tumours and mucosal melanoma of the sinonasal tract have been excluded, since dedicated guidelines already exist.
ER  -

RESTEGHINI, C.; B. BAUJAT; P. BOSSI; A. FRANCHI; L. DE GABORY; Jana HALÁMKOVÁ; F. HAUBNER; J. A. U. HARDILLO; M. A. HERMSEN; N A. IACOVELLI; R. MAROLDI; S. MATTHEIS; A. MOYA-PLANA; P. NICOLAI; E. ORLANDI; J. THARIAT; A. TRAMA; M. W. M. VAN DEN BREKEL; C. M. L. VAN HERPEN; B. VERILLAUD; E. KINLOCH; L. LICITRA a C. EVEN. Sinonasal malignancy: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up. \textit{ESMO OPEN}. AMSTERDAM: ELSEVIER, 2025, roč.~10, č.~2, s.~1-15. ISSN~2059-7029. Dostupné z: https://doi.org/10.1016/j.esmoop.2024.104121.

Přehled o publikaci